Like most websites, we use cookies and other similar technologies for a number of reasons, such as keeping our website reliable and secure, personalizing content, providing social media features and to better understand how our site is used. By using our site, you are agreeing to our use of these tools. Please review our Privacy Policy to learn more. 

Skip to Content

For everyone's safety, masks are required for everyone in our facilities. This includes visitors and patients. View visitor policy.

the beat

The Beat:
A Bryan Heart Blog

The Beat is a monthly blog from Bryan Heart cardiologists to keep you informed on trending topics, advancements and news in heart care.

Subscribe to receive The Beat to your inbox monthly.

Bryan Heart

To refer a patient to a Bryan Heart cardiologist or surgeon, call 402-483-3333.

Learn about Bryan Heart

New Diabetes Therapy Lowers Risk of Death from Cardiovascular Causes and
Could Reduce Weight and Blood Pressure 

Written by Bryan Heart Cardiologist, John Steuter, MD

Type 2 diabetes mellitus (T2DM) patients often suffer from obesity and hypertension, increasing their cardiovascular risk. To improve outcomes for patients with T2DM, empagliflozin (Jardiance) a sodium-glucose contransporter 2 inhibitor (SGLT2-I), was approved in 2015 as monotherapy or as an add-on therapy.

Testing the Effectiveness of Empagliflozin in Type 2 Diabetic Patients

The EMPA-REG OUTCOME trial was a randomized, double blind, placebo-controlled trial that investigated cardiovascular outcomes in patients with Type 2 diabetes at high risk of cardiovascular disease (CVD). They were treated with empagliflozin in addition to their standard of care. A group of 7,020 patients were randomized to receive empagliflozin vs. placebo.

Empagliflozin Proves Effective, Reasoning Unclear

Each component of the three-point major adverse cardiac event was evaluated. Patients treated with empagliflozin had a significantly lower risk (38%) of death from cardiovascular causes, but the risk of non-fatal MI and non-fatal stroke remained similar between groups. The primary outcome occurred in a significantly lower percentage of patients treated with empagliflozin than those receiving placebo (10.5% vs. 12.1%).  

EMPA-REG OUTCOME: Death from any cause

The reason for improved cardiovascular and renal outcomes is unclear. Overall, patients treated with empagliflozin plus standard of care had:

  • Lower HbA1c levels, though not necessarily meeting target values
  • Reduction in weight
  • Lower blood pressure
  • Increased levels of both LDL and HLD cholesterol

Increased weight loss could have contributed to the improved cardiovascular and renal outcomes. However, the reduction in CV risk factors, such as blood pressure and body weight, while statistically significant, were minimal and the differences observed within 2-4 months make it unlikely that the improved CV outcomes were due solely to modification of the CV risk.

Questions Remain, Future Studies May Answer

The question remains as to whether this improvement is a class effect or an outcome specific to empagliflozin. Studies with other SGLT2 inhibitors –  canagliflozin (CANVAS) and dapagliflozin (DECLARE-TIMI 58 trial – are in progress, which should help further answer some of these questions.

Register for the Bryan Heart Fall Cardiology Conference

Hear from Bryan Heart cardiologists on this topic and many other leading industry topics at the Bryan Heart fall conference on Saturday, Sept. 2, from 7:30 a.m.-5 p.m.

Register online today!

steuter john

About John Steuter, MD

John Steuter, MD, is a cardiologist at Bryan Heart. Steuter is a graduate of The University of Nebraska Medical Center College of Medicine and joined Bryan Heart in 2015 after completing his residency and fellowship at The University of Nebraska Medical Center. He is certified with the American Board of Internal Medicine.

View Dr. Steuter’s physician profile


Copyright 2022 Bryan Health. All rights reserved.